PATIENTS AND METHODS: All patients with metastatic (ovarian and extraovarian) CRC who underwent resection of ovarian metastases in our institution from April 1988 to August 2006 were analyzed and the response to preoperative chemotherapy was evaluated according to the RECIST criteria, and analyzed with respect to the sites of metastases (ovarian and extraovarian). RESULTS: The studied population consisted of 23 women. At presentation, 20 patients had symptoms. Preoperative chemotherapy resulted in tumor control of measurable extraovarian metastases in 65% of cases. In contrast, no objective tumor response of ovarian metastases was observed, disease stabilization was obtained in only 3 patients (13%), and progression or occurrence of new ovarian metastases were observed in 20 patients (87%) (p=0.0005). With a median follow-up of 54 months [15-229], median overall survival was 30 months, and 3-year overall survival was 18%. CONCLUSION: Ovarian metastases are less responsive to chemotherapy compared to other sites. As these "metastatic sanctuaries" often cause symptoms, surgical resection should always be considered for ovarian metastases, even in the case of associated extraovarian metastases.
PATIENTS AND METHODS: All patients with metastatic (ovarian and extraovarian) CRC who underwent resection of ovarian metastases in our institution from April 1988 to August 2006 were analyzed and the response to preoperative chemotherapy was evaluated according to the RECIST criteria, and analyzed with respect to the sites of metastases (ovarian and extraovarian). RESULTS: The studied population consisted of 23 women. At presentation, 20 patients had symptoms. Preoperative chemotherapy resulted in tumor control of measurable extraovarian metastases in 65% of cases. In contrast, no objective tumor response of ovarian metastases was observed, disease stabilization was obtained in only 3 patients (13%), and progression or occurrence of new ovarian metastases were observed in 20 patients (87%) (p=0.0005). With a median follow-up of 54 months [15-229], median overall survival was 30 months, and 3-year overall survival was 18%. CONCLUSION:Ovarian metastases are less responsive to chemotherapy compared to other sites. As these "metastatic sanctuaries" often cause symptoms, surgical resection should always be considered for ovarian metastases, even in the case of associated extraovarian metastases.
Authors: Praveen S Kammar; Reena Engineer; Prachi S Patil; Vikas Ostwal; T S Shylasree; Avanish P Saklani Journal: Indian J Surg Oncol Date: 2017-05-21
Authors: Karuna Ganesh; Ronak H Shah; Efsevia Vakiani; Garrett M Nash; Hugh P Skottowe; Rona Yaeger; Andrea Cercek; Anne Lincoln; Christina Tran; Neil H Segal; Diane L Reidy; Anna Varghese; Andrew S Epstein; Yukio Sonoda; Dennis Chi; Jose Guillem; Larissa Temple; Philip Paty; Jaclyn Hechtman; Jinru Shia; Martin Weiser; Julio Garcia Aguilar; Nancy Kemeny; Michael F Berger; Leonard Saltz; Zsofia K Stadler Journal: Cancer Date: 2016-11-22 Impact factor: 6.860
Authors: Carling Ursem; Margaret Zhou; Alan Paciorek; Chloe E Atreya; Andrew H Ko; Alan Venook; Li Zhang; Katherine Van Loon Journal: Oncologist Date: 2020-02-07
Authors: Wafik S El-Deiry; Namrata Vijayvergia; Joanne Xiu; Angelique Scicchitano; Bora Lim; Nelson S Yee; Harold A Harvey; Zoran Gatalica; Sandeep Reddy Journal: Cancer Biol Ther Date: 2015 Impact factor: 4.742